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Introduction 
Diabetes mellitus is one of the most 
challenging and prevalent metabolic diseases which 
results in microvascular complications such as 
retinopathy, neuropathy and macrovascular 
complications such as heart attack, stroke and 
peripheral vascular diseases.1 Diabetic retinopathy 
(DR) is a major cause of blindness in diabetes which 
can be avoidable with good glycemic control. There 
are number of factors that contribute to vascular 
permeability and angiogenesis in DR including the 
oxidative damage of the retinal neuronal cells, vascular 
endothelial growth factor (VEGF), prostaglandins, 
cyclooxygenase-2 (COX-2) and nitric oxide (NO) 
synthase.2 Despite the standards of care, laser 
photocoagulation and pars plana vitreous surgery for 
DR, recent successful use of several molecules is 
bringing a paradigm shift in favor of 
pharmacotherapy.3 There is an increasing interest in 
natural products in pharmacotherapy as the chemical 
diversity of natural products has better matches than 
the diversity of synthetic compounds.4 Flavonoids, a 
common group of plant polyphenols are known for 
their antioxidant, anti-inflammatory, anti-angiogenic 
activities also shown their potential in the prevention 
and treatment of various ocular diseases.5 
 
Nobiletin and diabetic retinopathy 
 
Parker and Addepalli6 investigated the effects 
of four weeks treatment of nobiletin, a citrus flavonoid 
on DR in streptozotocin induced diabetic rats. 
Outcomes indicated that treatment with nobiletin 
could be beneficial in amelioration of DR in 
experimental animals. Though there are number of 
studies showing the inhibitory activity of nobiletin on 
Matrix Metalloproteinase (MMP)-2 and MMP-9, they 
were mainly focused on various cancer treatments.7,8 
The approach of using nobiletin in the treatment of 
DR is a timely and significant approach. There are 
only limited investigations available on the use of 
flavonoids in blood retinal barrier permeability for e.g. 
diosmin and eriodictyol significantly ameliorates retinal 
edema by protecting the blood retinal barrier and 
reducing retinal vascular permeability.9,10 The 
Histopathological analysis on retinal thickness and 
retinal barrier permeability with nobiletin could be 
commendable and indicate direct and hard end point.  
In a situation, where the exact mechanism by 
which hyperglycemia causes blindness remains 
incompletely understood, this study clearly indicates 
that the mechanism of action of nobiletin is not by 
glucose lowering mechanism. This reveals a less 
complicated direction for a more complex question. In 
addition, the results showed lower doses of nobiletin 
(10mg/kg) did not have any significant effect on blood 
retinal barrier permeability compared to higher dosage 
(25 mg/kg).  This leads to further investigation on the 
dosage, bioavailability and the ocular concentrations of 
nobiletin. It is noteworthy to recall that the drug 
delivery to the ocular tissues is still a challenging task. 
 
Future directions 
 
This article is highly recommended for its new 
approach in showing the therapeutic implications of 
nobiletin for the treatment of DR. It provides a 
valuable perspective for future investigations to use 
other bioflavonoids in the prevention and treatment of 
DR. In addition, the results from this study navigates 
the further research on the mode of drug delivery via 
topical or local administration to yield effective 
concentrations at much lower doses. Above all, this 
article supports the fact that the use of phytochemicals 
is inevitable in order to increase the therapeutic 
activity and reduce toxicity in diabetes treatment. 
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